SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (18756)4/7/1998 5:43:00 PM
From: WTDEC  Read Replies (2) | Respond to of 32384
 
"The chemical structure of Fareston differs from that of tamoxifen, a widely-used antiestrogen, by the substitution of a chlorine atom for a hydrogen atom in the 4-position of the ethyl prosthetic group of the molecule"

Henry, do you know how Targretin's molecular structure and method of action differs from tamoxifen?

Regards,

Walter



To: Henry Niman who wrote (18756)4/7/1998 9:03:00 PM
From: John O'Neill  Read Replies (1) | Respond to of 32384
 
Could we have more info on Targretin; or, at least how LGND's drugs interact to make $$. It seems as though we've had a lot of repetitive posts on Tamaxofin and now Fareston.

Anyone know the time frame for our Targretin and the % chance of success? Rememer, Zantac well surpassed Tagamet as the drug of choice even though it came out later.

JO


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News